BIODESIX INC (BDSX): Results of Operations and Financial Condition
BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the reported Q2 revenue, gross margin, cash balance, and Adjusted EBITDA trajectory, while also tracking whether the company can sustain the $108–114M revenue guidance midpoint growth rate.
Market read
Fresh quarterly results plus reaffirmed full-year guidance are the core catalyst for BDSX positioning and estimate revisions.
What to watch
Development Services revenue declined year over year ($1.5M vs $2.1M), and operating expenses rose 7% despite leverage claims, which could matter if growth slows.
Background
This is an SEC Form 8-K with Exhibit 99.1 covering Biodesix Q2 2026 results and FY 2026 outlook.
Ticker impact
Biodesix reported Q2 2026 revenue of $26.9M (+34% YoY), 82% gross margin, and maintained FY 2026 revenue guidance of $108–114M.
Likely positive bias for the next session as traders reprice growth and margin trajectory versus prior expectations.
The filing includes multiple concrete performance datapoints (revenue growth, gross margin, Adjusted EBITDA improvement) plus unchanged FY guidance, giving traders actionable inputs for forward models.
Market effects
Supports the diagnostics/lung-cancer testing narrative around reimbursement coverage and operating leverage, potentially improving sentiment for similar commercial-stage diagnostic names.
Limited, primarily company-specific impact for US small/mid-cap biotech/diagnostics.
Low, as the disclosure is US-focused financial reporting and guidance.
Counterpoint
Strong gross margin and revenue growth may still be offset by continued net losses and execution risk in sustaining volumes and payer coverage.
Key entities
- companyBIODESIX, INC.
Nasdaq-listed diagnostic solutions company reporting Q2 2026 results and reaffirming FY 2026 revenue guidance.
- personScott Hutton
CEO quoted on growth drivers, gross margin expansion, and progress toward profitability.
